The FDA today posted a warning letter sent to LeMaitre (LMAT), dated August 11, following an inspection of the company’s North Brunswick, New Jersey facility. The inspection revealed that LeMaitre’s Artegraft collagen vascular grafts are adulterated. Shares of LeMaitre closed Tuesday down 2% to $95.28.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LMAT: